The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women. 1995

J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
Endocrine Service, Hospital das Clínicas de São Paulo, Brazil.

This study explored the effect of the anti-androgen spironolactone on sex-hormone binding globulin (SHBG) and the distribution of circulating testosterone (T) into various free and bound fractions in seven women with hirsutism assessed before and then monthly for three months on a regimen of spironolactone, 100 mg bid as the sole therapeutic agent. Blood samples were taken at each assessment time for a battery of androgen parameters and serum T fractions studies. None of the women were judged obese based upon body mass index values. After three months of spironolactone therapy, there was little change in the hirsutism index, and measurement of serum T, androstenedione, DHEA-S and 17 beta-estradiol showed no significant changes, the same occurring with SHBG-binding capacity. However, there was a shift in the distribution of circulating T, with a decrease in SHBG-bound T and an increase in albumin-bound and free T (non-SHBG-bound fractions). As previous reports suggest that non-SHBG-bound fractions represent bioavailable fractions, the current data suggests that T fraction studies may not be clinically useful parameters of hyperandrogenism in women receiving antiandrogen therapy.

UI MeSH Term Description Entries
D008598 Menstruation The periodic shedding of the ENDOMETRIUM and associated menstrual bleeding in the MENSTRUAL CYCLE of humans and primates. Menstruation is due to the decline in circulating PROGESTERONE, and occurs at the late LUTEAL PHASE when LUTEOLYSIS of the CORPUS LUTEUM takes place.
D011085 Polycystic Ovary Syndrome A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading. Stein-Leventhal Syndrome,Polycystic Ovarian Syndrome,Polycystic Ovary Syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary Syndrome,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,Sclerocystic Ovary,Stein Leventhal Syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D003687 Dehydroepiandrosterone A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion. Dehydroisoandrosterone,Prasterone,5-Androsten-3-beta-hydroxy-17-one,5-Androsten-3-ol-17-one,Androstenolone,DHEA,Prasterone, 3 alpha-Isomer,5 Androsten 3 beta hydroxy 17 one,5 Androsten 3 ol 17 one,Prasterone, 3 alpha Isomer
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006628 Hirsutism A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.
D006727 Hormone Antagonists Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. Antagonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
March 1985, Nihon Sanka Fujinka Gakkai zasshi,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
January 1982, International journal of fertility,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
September 1988, Clinical chemistry,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
January 1996, European journal of applied physiology and occupational physiology,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
September 1980, Scandinavian journal of clinical and laboratory investigation,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
July 1987, Metabolism: clinical and experimental,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
July 1995, The Journal of clinical endocrinology and metabolism,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
July 1982, Fertility and sterility,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
August 1987, Clinical chemistry,
J A Marcondes, and S L Minanni, and W W Luthold, and A C Lerário, and M Nery, and B B Mendonça, and B L Wajchenberg, and M A Kirschner
May 1982, Clinical endocrinology,
Copied contents to your clipboard!